Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (3r,5as,6r,8as,9r,12s,12ar)-3,6,9-trimethyloctahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10(3h)-one
2. Arteannuin
3. Artemisinine
4. Artemisininum
5. Huanghuahaosu
6. Qing Hao Su
7. Qinghaosu
8. Quing Hau Sau
9. Quinghaosu
1. Qinghaosu
2. 63968-64-9
3. Huanghuahaosu
4. Artemisinine
5. Artemisine
6. (+)-artemisinin
7. Artemisinina
8. Artemisininum
9. Artemisinin [inn]
10. Qing Hau Sau
11. Nsc 369397
12. Chebi:223316
13. Octahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10(3h)-one
14. 9rmu91n5k2
15. Qinghosu
16. Quing Hau Sau
17. Astemisinin
18. (1r,4s,5r,8s,9r,12s,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
19. (3r,5as,6r,8as,9r,12s,12ar)-3,6,9-trimethyloctahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10(3h)-one
20. (3r,5as,6r,8as,9r,12s,12ar)-octahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano(4,3-j)-1,2-benzodioxepin-10(3h)-one
21. Qing Hau Su
22. Qinghaosu [chinese]
23. Artemisinine [french]
24. Artemisininum [latin]
25. Artemisinina [spanish]
26. (+)-arteannuin
27. Qing Hau Sau [chinese]
28. Mfcd00081057
29. Artemisia Annua L., Extract
30. (1r,4s,5r,8s,9r,12s,13r)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecan-10-one
31. (3r,5as,6r,8as,9r,12s,12ar)-3,6,9-trimethyloctahydro-3,12-epoxypyrano(4,3-j)(1,2)benzodioxepin-10(3h)-one
32. (3r,5as,6r,8as,9r,12s,12ar)-octahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano[4,3-j]-1,2-benzodioxepin-10(3h)-one
33. 1,5,9-trimethyl-(1r,4s,5r,9r,12s,13r)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-one
34. Smr000578089
35. Sr-01000802560
36. Gnf-pf-5341
37. Artemsinin
38. Brn 4194670
39. Unii-9rmu91n5k2
40. Artemesinin
41. Artesin
42. Nsc-369397
43. Qinghaosu,artemisinine
44. Spectrum_001351
45. Artemisinin [mi]
46. Prestwick0_000498
47. Prestwick1_000498
48. Prestwick2_000498
49. Prestwick3_000498
50. Spectrum2_001512
51. Spectrum3_001549
52. Spectrum4_000721
53. Spectrum5_001098
54. Artemisinin [inci]
55. Ec 700-290-5
56. Artemisinin [mart.]
57. Schembl60304
58. Artemisinin [usp-rs]
59. Artemisinin [who-dd]
60. Artemisinin [who-ip]
61. Bspbio_000395
62. Bspbio_002998
63. Kbiogr_000982
64. Kbioss_001831
65. Mls001097650
66. Mls001304036
67. Mls002153846
68. Divk1c_000656
69. Spbio_001583
70. Spbio_002316
71. Bpbio1_000435
72. Chembl269671
73. Gtpl9954
74. Dtxsid2040652
75. Kbio1_000656
76. Kbio2_001831
77. Kbio2_004399
78. Kbio2_006967
79. Kbio3_002498
80. Ninds_000656
81. Hms2090i17
82. Hms2096d17
83. Hms2267n09
84. Hms3269l13
85. Hms3413p13
86. Hms3677p13
87. Hms3713d17
88. Pharmakon1600-01503042
89. 3,12-epoxy-12h-pyrano[4,3-j]-1,2-benzodioxepin-10(3h)-one, Octahydro-3,6,9-trimethyl-, (3r,5as,6r,8as,9r,12s,12ar)-
90. Bcp02096
91. Hy-b0094
92. Zinc8143788
93. Artemisininum [who-ip Latin]
94. Bdbm50088447
95. Nsc758216
96. Akos024457231
97. Ccg-220498
98. Cs-1794
99. Db13132
100. Lmpr0103190003
101. Nsc-758216
102. Idi1_000656
103. (3r,5as,6r,8as,9r,12s,12ar)-3,6,9-trimethyloctahydro-12h-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(3h)-one
104. 3,12-epoxy-12h-pyranol(4,3-j)-1,2-benzodioxepin-10(3h)-one, Octahydro-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12ar*)-(+)-
105. As-12692
106. S1282
107. 968a649
108. Q426921
109. Sr-01000802560-2
110. Sr-01000802560-3
111. Sr-01000802560-4
112. Brd-k13112821-001-08-3
113. Brd-k13112821-001-17-4
114. 2ab44f63-5d0f-424a-aa3f-24062f9c1ced
115. (3r,5as,6r,8as,9r,12s,12ar)-3,6,9-trimethyloctahydro-3,12-epoxypyrano(4,3-j )-1,2-benzodioxepin-10(3h)-one
116. (3r,5as,6r,8as,9r,12s,12ar)-3,6,9-trimethyloctahydro-3h-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10(12h)-one
| Molecular Weight | 282.33 g/mol |
|---|---|
| Molecular Formula | C15H22O5 |
| XLogP3 | 2.8 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 0 |
| Exact Mass | 282.14672380 g/mol |
| Monoisotopic Mass | 282.14672380 g/mol |
| Topological Polar Surface Area | 54 Ų |
| Heavy Atom Count | 20 |
| Formal Charge | 0 |
| Complexity | 452 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anti-Infective Agents
Substances that prevent infectious agents or organisms from spreading or kill infectious agents in order to prevent the spread of infection. (See all compounds classified as Anti-Infective Agents.)
P - Antiparasitic products, insecticides and repellents
P01 - Antiprotozoals
P01B - Antimalarials
P01BE - Artemisinin and derivatives, plain
P01BE01 - Artemisinin
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Artemisinin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Artemisinin, including repackagers and relabelers. The FDA regulates Artemisinin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Artemisinin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Artemisinin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Artemisinin supplier is an individual or a company that provides Artemisinin active pharmaceutical ingredient (API) or Artemisinin finished formulations upon request. The Artemisinin suppliers may include Artemisinin API manufacturers, exporters, distributors and traders.
click here to find a list of Artemisinin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Artemisinin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Artemisinin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Artemisinin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Artemisinin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Artemisinin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Artemisinin suppliers with NDC on PharmaCompass.
Artemisinin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Artemisinin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Artemisinin GMP manufacturer or Artemisinin GMP API supplier for your needs.
A Artemisinin CoA (Certificate of Analysis) is a formal document that attests to Artemisinin's compliance with Artemisinin specifications and serves as a tool for batch-level quality control.
Artemisinin CoA mostly includes findings from lab analyses of a specific batch. For each Artemisinin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Artemisinin may be tested according to a variety of international standards, such as European Pharmacopoeia (Artemisinin EP), Artemisinin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Artemisinin USP).
LOOKING FOR A SUPPLIER?
